Boston Scientific Corporation BSX

43.92 (0.76) (1.70%) as of 25 Sep
Market cap
$64.7B
P/E
17.7×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month

Boston Scientific Corporation (BSX) Debt to equity

Boston Scientific Corporation's debt to equity at the end of the quarter to 30 June 2026 was 0.5×, up 0.0× from fiscal 2025 (0.5×). Over the past ten years it has ranged from 0.5× (fiscal 2023) to 0.9× (fiscal 2015); the current reading is higher than 18% of that period. That is above the Medical Devices industry median of 0.1× and above the Healthcare sector median of 0.0×.

Debt to equity, annual

Annual

Period Debt to equity Change
FY2025 0.5× (4.32%)
FY2024 0.5× 4.78%
FY2023 0.5× (8.34%)
FY2022 0.5× (6.77%)
FY2021 0.5× (8.58%)
FY2020 0.6× (17.28%)
FY2019 0.7× (10.81%)
FY2018 0.8× 0.96%
FY2017 0.8× (1.67%)
FY2016 0.8× (9.33%)

Quarterly

Period Debt to equity Change
Jun 2026 0.5× 18.70%
Mar 2026 0.4× (9.59%)
Dec 2025 0.5× (4.81%)
Sep 2025 0.5× (4.03%)
42 more quarters

Against its own ten years

Low 0.5× High 0.9×
Ten-year median 0.6×
Current reading's percentile 18

Debt to equity against peers

Company Debt to equity
EW Edwards Lifesciences Corporation compare 0.1×
STE STERIS plc compare 0.3×
DXCM DexCom, Inc. compare 0.5×
BSX Boston Scientific Corporation 0.5×
PHG Koninklijke Philips N.V. compare 0.6×
MDT Medtronic PLC compare 0.6×
SYK Stryker Corporation compare 0.6×
ABT Abbott Laboratories compare 0.6×
GEHC GE HealthCare Technologies Inc. compare 1.0×
Medical Devices industry median 0.1×
Healthcare sector median 0.0×
Market median 0.2×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

More on BSX